BNP Paribas Financial Markets’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,485
| Closed | -$256K | – | 4309 |
|
|
2021
Q3 | $256K | Buy |
1,485
+703
| +90% | +$92K | ﹤0.01% | 2962 |
|
|
2021
Q2 | $98.1K | Buy |
782
+705
| +916% | +$88.9K | ﹤0.01% | 3049 |
|
|
2021
Q1 | $10.4K | Sell |
77
-1,720
| -96% | -$222K | ﹤0.01% | 3828 |
|
|
2020
Q4 | $230K | Buy |
1,797
+597
| +50% | +$70K | ﹤0.01% | 2817 |
|
|
2020
Q3 | $135K | Sell |
1,200
-42,173
| -97% | -$4.2M | ﹤0.01% | 2951 |
|
|
2020
Q2 | $4.13M | Buy |
43,373
+23,514
| +118% | +$2.27M | 0.01% | 1131 |
|
|
2020
Q1 | $1.78M | Buy |
19,859
+13,513
| +213% | +$1.05M | ﹤0.01% | 1550 |
|
|
2019
Q4 | $336K | Sell |
6,346
-1,749
| -22% | -$79.7K | ﹤0.01% | 2705 |
|
|
2019
Q3 | $320K | Buy |
8,095
+2,163
| +36% | +$93.8K | ﹤0.01% | 2470 |
|
|
2019
Q2 | $244K | Sell |
5,932
-4,219
| -42% | -$175K | ﹤0.01% | 2488 |
|
|
2019
Q1 | $473K | Buy |
10,151
+9,282
| +1,068% | +$408K | ﹤0.01% | 2128 |
|
|
2018
Q4 | $37.8K | Sell |
869
-1,306
| -60% | -$65.2K | ﹤0.01% | 2850 |
|
|
2018
Q3 | $124K | Buy |
2,175
+498
| +30% | +$24.5K | ﹤0.01% | 2629 |
|
|
2018
Q2 | $81.4K | Sell |
1,677
-6,092
| -78% | -$222K | ﹤0.01% | 2892 |
|
|
2018
Q1 | $304K | Buy |
7,769
+39
| +0.5% | +$1.66K | ﹤0.01% | 2534 |
|
|
2017
Q4 | $328K | Buy |
7,730
+4,316
| +126% | +$162K | ﹤0.01% | 2714 |
|
|
2017
Q3 | $127K | Sell |
3,414
-213
| -6% | -$7.39K | ﹤0.01% | 2667 |
|
|
2017
Q2 | $110K | Buy |
3,627
+3,288
| +970% | +$95.3K | ﹤0.01% | 2773 |
|
|
2017
Q1 | $8.97K | Sell |
339
-1,490
| -81% | -$39.3K | ﹤0.01% | 3191 |
|
|
2016
Q4 | $46.7K | Sell |
1,829
-292
| -14% | -$9.25K | ﹤0.01% | 2864 |
|
|
2016
Q3 | $76.8K | Buy |
2,121
+1,041
| +96% | +$34.5K | ﹤0.01% | 2230 |
|
|
2016
Q2 | $36.7K | Buy |
+1,080
| New | +$35.1K | ﹤0.01% | 2398 |
|
|
2016
Q1 | – | Sell |
-4,298
| Closed | -$210K | – | 3235 |
|
|
2015
Q4 | $210K | Sell |
4,298
-263
| -6% | -$9.46K | ﹤0.01% | 1900 |
|
|
2015
Q3 | $114K | Buy |
4,561
+2,637
| +137% | +$79.3K | ﹤0.01% | 2310 |
|
|
2015
Q2 | $60.9K | Buy |
1,924
+1,532
| +391% | +$49.4K | ﹤0.01% | 2370 |
|
|
2015
Q1 | $14.9K | Buy |
+392
| New | +$15.6K | ﹤0.01% | 2523 |
|
|
2014
Q4 | – | Sell |
-889
| Closed | -$26.9K | – | 3475 |
|
|
2014
Q3 | $26.9K | Buy |
+889
| New | +$25K | ﹤0.01% | 2961 |
|
|
2014
Q2 | – | Sell |
-7
| Closed | -$240 | – | 3998 |
|
|
2014
Q1 | $240 | Sell |
7
-72
| -91% | -$3.25K | ﹤0.01% | 3178 |
|
|
2013
Q4 | $3.13K | Buy |
+79
| New | +$1.91K | ﹤0.01% | 3399 |
|
BNP Paribas Financial Markets's XLRN Position: Q4 2021 in Review
BNP Paribas Financial Markets sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 1,485 shares — an estimated $256K sold.
BNP Paribas Financial Markets first reported a position in XLRN in Q4 2013 and held it in 29 quarters. The position peaked at $4.13M in Q2 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- BNP Paribas Financial Markets reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- BNP Paribas Financial Markets sold 1,485 Acceleron Pharma shares in Q4 2021, an estimated $256K.
- BNP Paribas Financial Markets first reported a position in Acceleron Pharma in Q4 2013 and held it in 29 quarters.
- BNP Paribas Financial Markets's Acceleron Pharma position peaked at $4.13M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2021, filed 9 Feb 2022.